Cameron Lesions

Introduction

Cameron lesions, also known as Cameron mucosal defects, are linear erosions that arise in the gastric antrum, typically within the proximal lesser curvature or near the pyloric channel. These lesions are most commonly associated with duodenal ulcer disease and are recognized as a potential source of overt gastrointestinal bleeding. First described in the early 1960s, Cameron lesions have since been the focus of clinical investigation into their pathogenesis, diagnosis, and management. Their identification has significant implications for patients presenting with upper gastrointestinal hemorrhage, especially when conventional endoscopic evaluation fails to reveal an obvious ulcer or polypoid lesion. The following article presents an in‑depth examination of Cameron lesions, covering historical context, underlying mechanisms, clinical features, diagnostic strategies, therapeutic approaches, and ongoing research directions.

Historical Background

Early Descriptions

The term “Cameron lesion” originates from the work of Dr. R. S. Cameron and colleagues in the early 1960s. Their seminal report detailed the observation of linear erosions in the gastric antrum of patients undergoing upper endoscopy for duodenal ulcer disease. The authors noted that these erosions were distinct from the classic ulcerative lesions typically found in the duodenum or gastric body, and they posited that the mechanical forces at the pyloric ring might contribute to their development. Subsequent case series reinforced the association between Cameron lesions and duodenal ulceration, as well as their propensity to bleed.

Evolution of Diagnostic Criteria

With the advancement of endoscopic technology, the ability to visualize subtle mucosal changes in the gastric antrum improved. Early diagnostic criteria focused on the linear, shallow appearance of the lesion and its proximity to the pylorus. Over time, consensus guidelines incorporated additional features such as the presence of associated ulceration or an adjacent peptic ulcer, as well as the potential for recurrent bleeding. These criteria have been refined through multicenter registries and systematic reviews, leading to improved recognition of Cameron lesions in routine clinical practice.

Impact on Clinical Practice

The identification of Cameron lesions has altered the approach to upper gastrointestinal bleeding. Prior to their description, many patients with overt bleeding and normal endoscopic findings were considered to have obscure sources or non‑variceal bleeding of unknown origin. Recognizing that linear antral erosions can bleed has prompted clinicians to scrutinize the gastric antrum more meticulously, especially in patients with duodenal ulcers or gastric motility disorders. Consequently, the management of such patients has evolved to include targeted endoscopic therapy or prophylactic measures when appropriate.

Pathophysiology

Mechanical Factors

One prevailing hypothesis posits that Cameron lesions arise from mechanical stress exerted on the gastric mucosa by the passing food bolus and gastric contractions. The antrum, situated just proximal to the pyloric sphincter, is subjected to increased pressure during gastric emptying. Repeated exposure to this mechanical force may lead to focal mucosal ischemia and subsequent erosion. Studies utilizing high‑resolution manometry have demonstrated elevated antral pressure in patients with Cameron lesions, supporting the mechanical injury theory.

Acid Exposure and Peptic Ulcer Disease

Acid secretion plays a central role in the development of peptic ulcer disease. Cameron lesions are frequently found in patients with duodenal ulcers, suggesting a shared pathogenesis involving excessive gastric acid. The antrum’s exposure to acid, coupled with a compromised mucosal barrier, predisposes it to erosion. Furthermore, the presence of Helicobacter pylori infection, a well‑established risk factor for peptic ulcer disease, has been documented in a subset of patients with Cameron lesions, reinforcing the link between acid‑mediated injury and lesion formation.

Impaired Mucosal Defense Mechanisms

Deficiencies in protective factors such as mucous and bicarbonate secretion, decreased prostaglandin synthesis, and impaired epithelial cell restitution can exacerbate mucosal vulnerability. Non‑steroidal anti‑inflammatory drug (NSAID) use, which inhibits cyclo‑oxygenase enzymes and reduces prostaglandin production, has been reported in many patients with Cameron lesions. Moreover, conditions that impair mucosal blood flow, including systemic hypoperfusion and chronic liver disease, may further compromise the integrity of the gastric epithelium, facilitating lesion development.

Inflammatory and Microbial Contributions

Helicobacter pylori infection induces chronic gastritis characterized by neutrophilic infiltration and mucosal damage. The inflammatory milieu can weaken the mucosal barrier, making it susceptible to mechanical stress and acid injury. In addition, the bacterial virulence factors CagA and VacA are implicated in mucosal damage and may contribute to the pathogenesis of Cameron lesions indirectly by intensifying inflammatory responses.

Epidemiology

Incidence and Prevalence

Cameron lesions are considered relatively uncommon, with estimates of incidence ranging from 1% to 5% of patients undergoing endoscopy for upper gastrointestinal bleeding. The prevalence appears higher in patients with confirmed duodenal ulcers or gastric acid hypersecretion. Large retrospective studies have reported that up to 15% of patients with peptic ulcer disease harbor concomitant Cameron lesions, underscoring the need for careful endoscopic evaluation in this population.

Risk Factors

Key risk factors include:

Duodenal ulcer disease
NSAID or aspirin use
Helicobacter pylori infection
Advanced age, particularly above 65 years
Male sex, though gender differences remain modest
History of prior gastric surgery (e.g., partial gastrectomy, pyloroplasty)

Additionally, comorbid conditions such as chronic kidney disease and cirrhosis may increase susceptibility due to altered acid metabolism or impaired mucosal healing.

Demographic Distribution

While Cameron lesions have been reported across all ethnic groups, the majority of case series originate from Western countries, reflecting the prevalence of peptic ulcer disease in these populations. However, emerging data from Asia, particularly Japan and Korea, indicate that the lesions are present in patients with H. pylori‑associated gastritis and are being increasingly recognized due to widespread endoscopic screening programs.

Clinical Presentation

Bleeding Phenotypes

The most frequent clinical manifestation of Cameron lesions is overt gastrointestinal bleeding, presenting as hematemesis, melena, or hematochezia. The bleeding episodes may be episodic, with intervals of hemodynamic stability punctuated by sudden hemorrhage. In some cases, the bleeding is minor and self‑limited, while in others, it can precipitate hemodynamic instability requiring transfusion.

Non‑Bleeding Symptoms

Patients may also report epigastric discomfort or a sensation of fullness, though these symptoms are not specific and often overlap with those of duodenal ulcer disease. Rarely, Cameron lesions may be discovered incidentally during endoscopy performed for unrelated indications such as dyspepsia or gastric cancer screening.

Diagnostic Challenges

The subtle nature of Cameron lesions often results in underdiagnosis. When an endoscopic evaluation fails to identify a classic ulcer or polypoid lesion in a patient with overt bleeding, clinicians may overlook linear erosions in the antrum. Recurrent bleeding in such patients can lead to repeated endoscopies, increasing procedural burden and healthcare costs.

Diagnosis

Endoscopic Evaluation

Upper gastrointestinal endoscopy remains the gold standard for identifying Cameron lesions. The lesions typically appear as pale, linear, shallow erosions or fissures within the gastric antrum, often adjacent to the pyloric ring. They may be accompanied by an underlying ulcer or superficial erythema. Key endoscopic criteria include:

Linear morphology with a length of 5–15 mm
Shallow depth (
Location near the pylorus or within the lesser curvature
Absence of a distinct raised margin (in contrast to peptic ulcers)
Potential for visible vessels or stigmata of recent hemorrhage

High‑definition scopes and chromoendoscopy can enhance visualization, aiding in the detection of subtle erosions.

Radiologic Imaging

While computed tomography (CT) angiography is valuable for detecting active bleeding in the upper gastrointestinal tract, it typically lacks the resolution to identify small mucosal lesions such as Cameron defects. Capsule endoscopy may occasionally reveal antral erosions but is less reliable than conventional endoscopy due to limited visualization of the pyloric region. Thus, imaging plays a supplementary role, primarily for patients who are unstable or have inconclusive endoscopic findings.

Histopathologic Correlation

Biopsy specimens from Cameron lesions are rarely performed because the lesions are often superficial and bleed readily. When sampled, histology may reveal superficial mucosal necrosis, inflammatory infiltrate, and occasionally H. pylori organisms. However, these findings are non‑specific and do not distinguish Cameron lesions from other mucosal erosions.

Diagnostic Algorithm

An evidence‑based diagnostic approach includes:

Initial upper endoscopy in all patients presenting with upper gastrointestinal bleeding.
Careful inspection of the gastric antrum, especially the region proximal to the pylorus.
Use of high‑definition scopes and, when necessary, chromoendoscopy.
If a Cameron lesion is identified, assess for stigmata of recent hemorrhage.
If no lesion is seen but bleeding persists, consider repeat endoscopy or imaging studies.

Management

Endoscopic Therapy

When a Cameron lesion exhibits active bleeding or visible vessels, endoscopic hemostasis is the first‑line intervention. Standard techniques include:

Hemoclipping – application of mechanical clips to tamponade the vessel.
Injection therapy – epinephrine diluted in saline (1:10,000) injected adjacent to the lesion to induce vasoconstriction.
Thermal coagulation – argon plasma coagulation or bipolar coagulation to achieve hemostasis.

Combining modalities (e.g., epinephrine injection followed by clip placement) has been associated with lower rebleeding rates compared to single modalities. Endoscopic therapy is generally safe, with minimal complications such as perforation or post‑procedure pain.

Medical Management

Proton pump inhibitors (PPIs) are routinely administered to reduce gastric acid secretion and promote mucosal healing. Induction therapy typically involves intravenous PPI infusion for 24–48 hours, followed by oral dosing for at least 2 weeks. In patients with NSAID‑associated lesions, discontinuation of the offending agent is mandatory. For H. pylori‑positive patients, eradication therapy (commonly a triple or quadruple regimen) is recommended to reduce ulcer recurrence risk.

Adjunctive Measures

Patients with significant comorbidities, such as cirrhosis or coagulopathy, may benefit from additional interventions:

Vitamin K or fresh frozen plasma to correct coagulation deficits.
Transfusion of packed red blood cells to maintain hemoglobin above 7–8 g/dL in hemodynamically stable patients.
Consideration of angiographic embolization or surgical intervention in cases of refractory bleeding.

Preventive Strategies

Because Cameron lesions are associated with duodenal ulcers and other acid‑related disorders, primary prevention focuses on controlling acid secretion and eliminating mucosal irritants. Long‑term PPI therapy may reduce the incidence of new lesions. In patients with high bleeding risk (e.g., concurrent anticoagulation), a multidisciplinary approach involving gastroenterology, hematology, and cardiology is essential to balance hemorrhagic risk with thrombotic prevention.

Prognosis

Bleeding Outcomes

Studies report that rebleeding occurs in approximately 10–20% of patients after initial endoscopic hemostasis. Early rebleeding is associated with larger lesion size, presence of active spurting blood, and concurrent ulcer disease. However, with prompt re‑intervention and optimized medical therapy, most patients achieve durable hemostasis.

Mortality and Morbidity

Mortality related directly to Cameron lesion bleeding is relatively low (

Long‑Term Outcomes

In patients with concomitant duodenal ulcers, the overall risk of ulcer recurrence remains significant, especially if H. pylori persists or NSAID use continues. Longitudinal studies indicate that complete eradication of H. pylori and sustained PPI therapy reduce recurrence rates to below 5% per year. Conversely, in patients with persistent risk factors, recurrence may approach 20% annually, emphasizing the need for ongoing surveillance.

Duodenal Ulcer Disease

Duodenal ulcers and Cameron lesions frequently coexist. The presence of a duodenal ulcer may serve as a marker of heightened acid secretion and increased mucosal susceptibility, thereby predisposing the antrum to linear erosion formation.

Gastric Ulcer Disease

While less common, gastric ulcers located in the antrum can mimic the appearance of Cameron lesions. Differentiating between a shallow ulcer and a linear erosion is critical for appropriate management, particularly regarding the necessity of ulcer‑specific therapy versus targeted hemostasis.

Gastric Motility Disorders

Conditions such as gastroparesis or pyloric stenosis can alter the mechanical forces applied to the antrum, potentially exacerbating mucosal trauma. Patients with diabetic gastroparesis have shown an increased prevalence of antral erosions, though the causal relationship remains under investigation.

Helicobacter pylori‑Associated Gastritis

Chronic gastritis due to H. pylori infection can compromise mucosal defenses and is a recognized risk factor for peptic ulcer disease. The inflammatory cascade induced by H. pylori may also influence the susceptibility of the antrum to mechanical injury, thereby contributing to Cameron lesion formation.

Research and Controversies

Diagnostic Accuracy

There remains debate regarding the sensitivity of standard endoscopy for detecting Cameron lesions. Some studies propose that enhanced imaging modalities, such as narrow‑band imaging (NBI) or confocal laser endomicroscopy, could improve detection rates. However, large‑scale randomized trials comparing conventional scopes to advanced imaging techniques are lacking, limiting definitive conclusions.

Therapeutic Efficacy

The optimal endoscopic modality for achieving durable hemostasis in Cameron lesions is unclear. While combination therapy appears superior to monotherapy in ulcer bleeding, data specific to Cameron lesions are limited to case series and retrospective analyses. Prospective trials are needed to establish standardized treatment protocols.

Role of Long‑Term PPI Therapy

While PPI therapy is widely employed, its long‑term safety profile in patients with Cameron lesions is not fully understood. Concerns regarding chronic PPI use include bone demineralization, increased infection risk, and potential alteration of gastric microbiota. The balance between preventing recurrence and minimizing adverse effects remains a subject of ongoing research.

Impact of Anticoagulation

The interaction between anticoagulant therapy (e.g., warfarin, direct oral anticoagulants) and the risk of bleeding from Cameron lesions is poorly characterized. Some observational studies suggest that patients on anticoagulants are more likely to experience rebleeding, yet the data are inconsistent. A multidisciplinary consensus is required to guide anticoagulation management in this population.

Conclusion

Cameron lesions represent a distinct subset of acid‑related mucosal erosions that can cause significant upper gastrointestinal bleeding. Accurate diagnosis hinges on meticulous endoscopic examination of the gastric antrum. Management strategies integrate endoscopic hemostasis, acid suppression, and elimination of mucosal irritants, with PPIs and H. pylori eradication therapy playing central roles. Although mortality is low, rebleeding rates are appreciable, underscoring the need for prompt intervention and ongoing surveillance. Future research focused on diagnostic innovation and therapeutic standardization will enhance outcomes for patients affected by this often underrecognized entity.

Search

Table of Contents